{"id":945343,"date":"2026-03-18T08:34:32","date_gmt":"2026-03-18T12:34:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/"},"modified":"2026-03-18T08:34:32","modified_gmt":"2026-03-18T12:34:32","slug":"equillium-to-participate-in-the-38th-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/","title":{"rendered":"Equillium to Participate in the 38th Annual Roth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LA JOLLA, Calif., March  18, 2026  (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38<sup>th<\/sup> Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT.<\/p>\n<p>Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.<\/p>\n<p>\n        <strong>About Equillium<\/strong><br \/>\n        <br \/>Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company\u2019s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FVZyCaZa_f4qymxzyNF3JngJaTI0ZHgSWgZvzrZn8_0f_2SCHJSF1wljj_c-Ot0H9P6TV97Hy9tkoW3Y9aMKE4_0DIkyuJNX5NDmQRYqgYc=\" rel=\"nofollow\" target=\"_blank\">www.equilliumbio.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact\u00a0<\/strong><br \/>\n        <br \/>PJ Kelleher<br \/>LifeSci Advisors, LLC<br \/>+1-617-430-7579<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F2ftDisI-eixl_56r2pfBCMpJtqbyyHk9pm9g745TC8kfeYyqSKYAyhjJEeldm18aI_UshwJGBmKrGDJusnxkbD12CACCc3J3CmpadNsCnYwTlPjeXC1Bqj2XKge7K6mULLaqUg337uVg0QcpWS7Lqb7-D8Dx_GTRK7pqNzqu2z_m0X8CwJiIKmuTllxk2dfJXl-K2t0SmGdscn9SKo6Xp3FNwinLlVxZDM5zW9s97P9CKoB6g5S7mNeSaycIf7azK-CwZ2n4PbaP9sZkQ1HAMLRgD1gT5XaAuX8hnTt_EU1LeTlA56oBe4h9b_4e_dA\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzkxZmMxMDctYzlkNS00NTkwLTg3NWMtZjY1ZTVlNDQ4MDBkLTUwMDE1Mjg5Ni0yMDI2LTAzLTE4LWVu\/tiny\/Equillium-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About Equillium Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company\u2019s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Equillium to Participate in the 38th Annual Roth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945343","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Equillium to Participate in the 38th Annual Roth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Participate in the 38th Annual Roth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About Equillium Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company\u2019s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other &hellip; Continue reading &quot;Equillium to Participate in the 38th Annual Roth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T12:34:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Participate in the 38th Annual Roth Conference\",\"datePublished\":\"2026-03-18T12:34:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/\"},\"wordCount\":184,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/\",\"name\":\"Equillium to Participate in the 38th Annual Roth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==\",\"datePublished\":\"2026-03-18T12:34:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-participate-in-the-38th-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Participate in the 38th Annual Roth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Participate in the 38th Annual Roth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Participate in the 38th Annual Roth Conference - Market Newsdesk","og_description":"LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About Equillium Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company\u2019s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other &hellip; Continue reading \"Equillium to Participate in the 38th Annual Roth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T12:34:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Participate in the 38th Annual Roth Conference","datePublished":"2026-03-18T12:34:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/"},"wordCount":184,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/","name":"Equillium to Participate in the 38th Annual Roth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==","datePublished":"2026-03-18T12:34:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDEwMyM3NDkxMTY0IzUwMDE1Mjg5Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-participate-in-the-38th-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Participate in the 38th Annual Roth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945343"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945343\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}